Bruker (NASDAQ:BRKR) Stock Gets Price Target Boost from Citigroup

Bruker (NASDAQ:BRKR) had its price objective lifted by stock analysts at Citigroup from $53.00 to $64.00 in a research note issued on Thursday, Benzinga reports. The firm presently has a “neutral” rating on the medical research company’s stock. Citigroup‘s price objective would indicate a potential upside of 10.33% from the stock’s current price.

A number of other equities research analysts have also recently weighed in on the company. UBS Group initiated coverage on Bruker in a research report on Wednesday, September 9th. They issued a “neutral” rating and a $65.00 price objective for the company. Stifel Nicolaus set a $50.00 price objective on Bruker in a research note on Wednesday, August 5th. Barclays increased their target price on Bruker from $58.00 to $70.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. The Goldman Sachs Group upgraded Bruker from a “strong sell” rating to a “strong-buy” rating in a research note on Monday, September 21st. Finally, Guggenheim lifted their price target on Bruker from $70.00 to $72.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $60.57.

Bruker Price Performance

Shares of NASDAQ BRKR traded down $5.78 during mid-day trading on Thursday, hitting $58.01. 3,262,133 shares of the stock were exchanged, compared to its average volume of 2,383,511. The company has a market cap of $8.84 billion, a P/E ratio of -82.87, a PEG ratio of 1.73 and a beta of 1.26. The stock’s fifty day simple moving average is $58.95 and its two-hundred day simple moving average is $50.48. The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.92 and a current ratio of 1.85. Bruker has a twelve month low of $32.37 and a twelve month high of $68.98.

Bruker (NASDAQ:BRKR) last posted its earnings results on Wednesday, November 4th. The medical research company reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.42 by $0.14. The company had revenue of $874.00 million during the quarter, compared to analysts’ expectations of $865.16 million. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. Bruker’s quarterly revenue was up 1.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.45 earnings per share. As a group, analysts forecast that Bruker will post 2.12 EPS for the current fiscal year.

Insider Buying and Selling at Bruker

In related news, VP Mark Munch sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $52.87, for a total value of $105,740.00. Following the completion of the sale, the vice president owned 134,806 shares of the company’s stock, valued at $7,127,193.22. This trade represents a 1.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 27.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Bruker

Hedge funds and other institutional investors have recently made changes to their positions in the company. Pallas Capital Advisors LLC bought a new stake in shares of Bruker during the second quarter worth $570,746,000. Edmond DE Rothschild Holding S.A. bought a new position in Bruker in the second quarter valued at about $169,899,000. Sculptor Capital LP boosted its holdings in Bruker by 9.0% in the first quarter. Sculptor Capital LP now owns 3,270,000 shares of the medical research company’s stock valued at $118,112,000 after acquiring an additional 270,000 shares during the last quarter. Alyeska Investment Group L.P. boosted its holdings in Bruker by 86.2% in the second quarter. Alyeska Investment Group L.P. now owns 1,410,164 shares of the medical research company’s stock valued at $84,864,000 after acquiring an additional 653,007 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in Bruker by 23.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,341,518 shares of the medical research company’s stock worth $84,556,000 after purchasing an additional 448,440 shares during the last quarter. 79.52% of the stock is owned by institutional investors and hedge funds.

Bruker News Summary

Here are the key news stories impacting Bruker this week:

• Positive Sentiment: Bruker reported Q3 adjusted earnings of $0.56 per share, above the $0.42 consensus, and revenue of $874 million versus estimates of about $865 million. Revenue rose 1.6% year over year. Bruker Q3 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Management highlighted margin expansion and strong bookings, and said U.S. academic demand returned in Q3. The company also sees potential for double-digit EPS growth in fiscal 2027, although that outlook is forward-looking. Bruker Q3 2026 Earnings Call Highlights
• Neutral Sentiment: Bruker forecast 2026 revenue of $3.52 billion to $3.56 billion, compared with a FactSet estimate of $3.56 billion. Its adjusted EPS range of $2.10 to $2.15 broadly brackets the $2.12 estimate. Bruker 2026 Revenue Outlook
• Negative Sentiment: The outlook offered little upside to expectations, while coverage also flagged a steep goodwill charge that weighed on reported results. These concerns may have overshadowed the quarterly beat and contributed to the weaker share performance. Bruker Q3 2026: Margin Surge Masks a Steep Goodwill Charge

About Bruker

Bruker Corporation develops and manufactures scientific instruments, analytical systems and related software used to study materials, molecules and biological processes. Its technologies support research, discovery and quality control in fields including life sciences, pharmaceutical development, chemical analysis, materials science, environmental testing and clinical research.

The company’s product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, infrared and Raman spectroscopy instruments, X-ray analysis equipment, microscopy and nanoanalysis systems, and preclinical imaging technologies.